Neuroprotection is a recurring topic in our peptide coverage. This hub collects every article tagged Neuroprotection, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical, evidence-graded ranking of the peptides marketed for neuroprotection — Cerebrolysin, Semax, ARA-290, SS-31/elamipretide and P021 — separating a modest, mixed human signal from elegant but preclinical-only mechanism.
A clinical monograph on Semax — the Russian-developed ACTH(4-10) heptapeptide used intranasally for stroke recovery and cognition. Real but single-country human data, graded B, with an unsettled 2026 FDA status.
A clinical monograph on N-Acetyl Semax Amidate — the terminally-stabilized analog of the Russian nootropic Semax. No human or animal data on the modified molecule, an unproven potency story, and an unsettled 2026 legal status.
A clinical monograph on humanin — the first mitochondrial-derived peptide. Deep preclinical cytoprotection data, intriguing human biomarker correlations, zero interventional human trials, and a real tumor-promotion caveat.
A clinical monograph on SS-20 — the Szeto-Schiller mitochondria-targeting tetrapeptide that protects mitochondria without antioxidant chemistry. Deep preclinical data, no human trials, and unapproved research-only status in 2026.
A clinical monograph on FGL (FGLL) — the NCAM-derived FGFR1 agonist peptide marketed for memory and neuroprotection. Deep rodent data, one single-dose human safety study, and zero efficacy proof in people.
A clinical monograph on Pinealon (Glu-Asp-Arg / EDR), the Khavinson ultrashort neuroprotective tripeptide. Reproducible preclinical antioxidant data, no human RCT, and an unapproved 2026 legal status.
A clinical monograph on Cortagen (Ala-Glu-Asp-Pro) — the Khavinson-program 'cytogen' tetrapeptide marketed for nerve repair and neuroprotection. One intriguing rat nerve-regeneration signal, no human RCTs, and an unapproved-research-chemical legal status.
Neuroprotection is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Neuroprotection, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.